Alteogen Presents Potential for New Subcutaneous Injection Platform Development... PCT Application Filed

Published 22 Mar.2024 08:27(KST)

Alteogen announced on the 22nd that it has developed a new human hyaluronidase variant that can serve as the basis for a new subcutaneous injection formulation change platform and has filed an international patent application under the Patent Cooperation Treaty (PCT).

Alteogen exterior view [Photo by Alteogen]

General patent applications must be filed individually in each country. Even if a patent has already been granted domestically, if a similar patent is filed in another country during the period before the application is made there, the patent may not be recognized. A PCT application allows for simultaneous filing in 157 countries that are members of the PCT when filed in Korea.

The newly developed human hyaluronidase variant by Alteogen this time was developed using a different human hyaluronidase than Alteogen's existing subcutaneous injection formulation change platform technology, Hybrozyme, which was developed based on ALT-B4. Hybrozyme is a platform based on PH20, one of the five types of hyaluronidase present in the body.

The change of drug formulations to subcutaneous injections using recombinant hyaluronidase is currently mainly used for antibody drugs. The company expects that in the future, it will be possible to expand to various therapeutics such as antibody-drug conjugates (ADC) and small molecule compounds. In particular, there is anticipation that it can be applied to methods such as directly administering anticancer drugs to cancer cells to enhance the efficacy of anticancer agents.

An Alteogen representative said, "Through this PCT application, we aim to secure intellectual property rights to establish the possibility of developing a new platform for the new human hyaluronidase and position ourselves as the most advanced company regarding human hyaluronidase."